Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesHot NewsMost Read NewsRecomm.Business LeadersCalendar 

Zogenix Inc. : Trading of Zogenix Common Stock Halted

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/07/2012 | 02:00pm CET

FDA Advisory Committee Reviewing Zohydro™ ER New Drug Application

Zogenix to Host Conference Call at 6:30 pm ET Today

SAN DIEGO, Dec. 7, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, announced that NASDAQ halted trading of the company's common stock on December 7, 2012. The U.S. Food and Drug Administration's (FDA) Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) is meeting today to review the Company's New Drug Application (NDA) for Zohydro™ ER (hydrocodone bitartrate extended-release capsules).

Conference Call & Webcast

Zogenix will host a conference call to discuss the outcome of the AADPAC meeting today, Friday, December 7, 2012 at 6:30 p.m. ET (3:30 p.m. PT). To participate, please dial (800) 299-9086 (U.S.) or (617) 786-2903 (International); participant passcode: 21970283. To access the live webcast please visit the Zogenix Investor Relations website at http://ir.zogenix.com.  

The conference call will be hosted by Chief Executive Officer Roger L. Hawley and President and Chief Operating Officer Stephen J. Farr, Ph.D.

A replay of the conference call will be available beginning December 7, 2012 at 8:30 p.m. ET (5:30 p.m. PT) until December 14, 2012, by dialing (888) 286-8010 (U.S.) or (617) 801-6888 (International); passcode: 27116437. A replay of the webcast will also be accessible on the Investor Relations website for one month, through January 10, 2013.

About Anesthetic and Analgesic Drug Products Advisory Committee

The AADPAC reviews and evaluates available data concerning the safety and effectiveness of marketed and investigational human anesthetic and analgesic drug products and makes appropriate recommendations to the Commissioner of Food and Drugs. The AADPAC provides FDA with independent expert advice and recommendations, however, the final decision regarding approval is made by FDA.

About Zogenix

Zogenix, Inc., with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL® DosePro® (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead investigational product candidate, ZohydroTM ER (hydrocodone bitartrate) is an oral, novel extended-release formulation of various strengths of hydrocodone without acetaminophen intended for administration every 12 hours for around the clock management of moderate to severe chronic pain. Zogenix's second DosePro investigational product candidate, ReldayTM, is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia. In May 2012, Zogenix submitted to the FDA a New Drug Application for Zohydro ER and an Investigational New Drug Application for Relday. The FDA assigned a PDUFA target action date of March 1, 2013 for the Zohydro ER NDA.

For additional information, please visit www.zogenix.com.

SUMAVEL ®, DosePro ®, ReldayTM and ZohydroTM ER are trademarks of Zogenix, Inc.

CONTACT: INVESTORS:
         Zack Kubow | The Ruth Group
         646.536.7020 | zkubow@theruthgroup.com

         MEDIA:
         Emily Poe | WCG
         212.301.7183 | epoe@wcgworld.com
Zogenix
distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news
Date Title
03:50a COPS : Fired employee shot popular Wendy's manager in Apopka
03:49a PACIFIC ANDES INTERNATIONAL : Update to bondholders
03:44a CHIWAYLAND INTERNATIONAL : 20161205 notice of expiry of warrants
03:44a MNRL HILL : Vancouver, BC – December 5, 2016
03:44a STONE ENERGY CORPORATION : Announces Amethyst Operational Update
03:43a Lawmakers ask U.S. to block Chinese takeover of Lattice Semiconductor
03:41a NORDIC NANOVECTOR : Betalutin® in Combination with rituximab Demonstrates Synergistic Anti-Tumour Effect in Preclinical non-Hodgkin Lymphoma Model
03:39a DEPARTMENT OF INDUSTRY AND SCIENCE AUSTRALIAN GO : Canavan welcomes Adani's regional commitment
03:35a Asia stocks bounce as risk appetite returns after Italy vote
03:34a ALBERTSONS : Dunnavan is arrested for robbing the Family Dollar
Latest news
Advertisement
Hot News 
-5.36%Eddie Lampert proposes to buy further stake in Sears Hometown
3.23%BAYERISCHE MOTOREN WERKE : BMW seeks to be 'coolest' ride-hailing firm with autonomous car
0.24%WALL STREET STOCK EXCHANGE : Wall Street rises, buoyed by economic data; Dow sets high
2.40%VOLKSWAGEN : Audi extends job guarantees for German staff to 2020
1.51%AIRBUS : chief wants soft Brexit, higher German military budget
Most Read News
06:13p FORD MOTOR : to raise $2.8 billion debt to fund new technology
07:03p UNITED TECHNOLOGIES : UTC CEO says no 'quid pro quo' on keeping Indiana plant open
06:19p BANK OF NOVA SCOTIA : Industrial Alliance Enters into Agreement to Acquire HollisWealth from Scotiabank
06:15pDJU.S. Tech Firms to Join Forces on Take Down of Terror Content
06:30p LITHIUM X ENERGY : Begins Trading on the OTCQX
Most recommended articles
12/02 Platts considers first addition to Brent basket since 2007
11/30DJCash Crunch Looms Over India's Growth Spurt
09:43p Lawmakers ask U.S. to block Chinese takeover of Lattice Semiconductor
09:27p ADANI ENTERPRISES : India's Adani Enterprises Australia CEO says coal project 'back on track'
09:16pDJNEWS HIGHLIGHTS : Top Global Markets News of the Day